TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06707051
Drug: Calcium dobesilate (Doxium)
Normalized name: calcium dobesilate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B recieved Cap.Calcium Dobesilate 500mg 3 times a day for 5 days
Study: NCT06709716
Drug: Local Anesthetic Solution
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative injection of 0.25% bupivacaine at each incision site
Study: NCT06709716
Drug: Local Anesthetic Solution
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative injection of saline at each incision site.
Study: NCT06758752
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, applied twice daily for 3 weeks after enrolment
Study: NCT06781970
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be given placebo, tid, for 7 days prior to phacoemulsification and 4 weeks after phacoemulsification
Study: NCT02069288
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet of placebo per os
Study: NCT05935527
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be randomized to receive three injections of 120 microliters total of Normal Saline per under eyebag at each of three treatment visits.
Study: NCT05113901
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 21 sugar tablets at 6 weeks with standard management, qualifying for MUA if ROM \<90° at 8 weeks
Study: NCT06798519
Drug: HNC364 Injectable Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects in HNC364 cohort will receive a deep IM injection of HNC364 injectable suspension in the deltoid muscle at a dose of 60 mg every 4 weeks for 4 repeated doses. Subjects will be allowed to leave the clinical site the next day after receiving each dose and return to clinical site on 7 days, 14 days and 28 days (before next administration) after each dose for safety and tolerability assessments. Besides, subjects will return to the clinical site on 4 days after the first dose and the last dose due to PK and PD blood sample collections.
Study: NCT05285332
Drug: Systemic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine therapy or chemotherapy or targeted therapy
Study: NCT05131997
Drug: AD-221C
Approvals — FDA: no, EMA: no, PMDA: no
Description: PO, Once daily(QD), 8 weeks
Study: NCT05405114
Drug: NDec - oral decitabine-tetrahydrouridine
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will get capsules (oral administration) to take once or twice weekly. The number of capsules will be based on their body weight
Study: NCT05405114
Drug: HU - Hydroxyurea
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will get capsules daily (oral administration) according to local labelling
Study: NCT05405114
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will get capsules (oral administration) to take once or twice weekly. The number of capsules will be based on their body weight
Study: NCT05602311
Drug: General anesthetic
Normalized name: General anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monitoring the changes of brain functional connectivity and assess cognition in two groups after general anesthesia
Study: NCT06550024
Drug: Corticosteroid Injection
Normalized name: CORTICOSTEROIDS
DrugBank: Corticosterone (DB04652)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid injection in the knee
Study: NCT06447480
Drug: Topical cream
Normalized name: Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical retinoic acid (Effederm®) or adapalene cream (Differine®), associated during the 3 first months with doxycycline or lymecycline 100 mg/d. After 3 months, the efficacy is assessed. If acne improved, oral antibiotics are stopped and only the topical treatment is continued. If the ECLA is graded as moderated or severe, isotretinoin should be introduced.
Study: NCT06306612
Drug: Systemic Chemohormonal Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Under continuous ADT, docetaxel 75mg/m\^2 body surface area every 21 days, oral dexamethasone 7.5mg pretreatment 12h, 3h, 1h before each infusion of docetaxel, and a total of 10mg of prednisolone per day when needed according to the decision of the researcher (in the case of grade 3 and above neutropenia or peripheral edema); oral darolutamide 600mg twice per day, 21 days for one cycle, six cycles in total.
Study: NCT05858164
Drug: BAY2862789
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration, solution or tablets
Study: NCT06532006
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 1000 mg/m2 bid on Days 1-14 ,Q3W
Study: NCT06510062
Drug: 2.5% Diclofenac Patches
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical pain relief gel worn via SAM patch.
Study: NCT05476042
Drug: Prescription of placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline
Study: NCT04249063
Drug: Xylocaine 1 % and Normal Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3cc aliquots of local anaesthetic will be injected into the right and left cornual regions and centrally in the fundus. This will be achieved by using a flexible hysteroscopic needle.
Study: NCT04632992
Drug: Investigator's Choice of Chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy will consist of docetaxel, paclitaxel, or capecitabine, as determined by the investigator, and will be administered per the respective package insert and institutional guidelines.
Study: NCT04249063
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3cc aliquots of normal saline will be injected into the right and left cornual regions and centrally in the fundus. This will be achieved by using a flexible hysteroscopic needle.
Study: NCT06333041
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral solution is a yellow oily solution containing the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring
Study: NCT05846867
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluorouracil 400mg/m2, intravenous injection
Study: NCT04234022
Drug: Lanalidomide with Zn-DDC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanalidomide with Zn-DDC added to myeloma samples for culturing
Study: NCT05133336
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects randomized to placebo arm will receive placebo treatment for the entire treatment period up to Week 52.
Study: NCT04670068
Drug: CAR.B7-H3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two dose levels will be evaluated: Dose Level 1 (7.5x10\^7 cells/infusion), dose Level 2 (2x10\^8 cells/infusion). If dose limiting toxicities (DLTs) are observed per protocol, Dose Level -1 (3.75x10\^6 cells/infusion) will be evaluated.
Study: NCT04670068
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 300 mg/m\^2 IV for 3 consecutive days
Study: NCT05492019
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline 50 mg capsule twice daily for 8 weeks.
Study: NCT05492019
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo identical to Doxycycline
Study: NCT04652700
Drug: ISL
Normalized name: Dartisla
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISL 60 mg tablet, QM, orally for up to 24 months
Study: NCT04652700
Drug: FTC/TDF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants receive 200/245 mg of FTC/TDF combination tablet, QD, orally for up to 24 months
Study: NCT04652700
Drug: FTC/TAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants receive 200/25 mg of FTC/TAF combination tablet, QD, orally for up to 24 months
Study: NCT04652700
Drug: Placebo to ISL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo ISL 0 mg tablets QM, orally for up to 24 months.
Study: NCT04652700
Drug: Placebo to FTC/TDF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo FTC/TDF 0 mg tablets QD, orally for up to 24 months
Study: NCT04652700
Drug: Placebo to FTC/TAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo FTC/TAF 0 mg tablets QD, orally for up to 24 months
Study: NCT05289063
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo daily for 28 days will be randomly allocated to OSA patients regardless of adherence with CPAP. Atorvastatin and placebo will be encapsulated to appear identical and dispensed by the research pharmacy.
Study: NCT05955066
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 capsule daily
Study: NCT06098833
Drug: Ora-Blend
Normalized name: Ora-Blend Syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ora-Blend per os twice a day for seven consecutive days (from day 2 of life to day 9 of life) if brain injury on day 2 of life (dose 1=2mg/kg/dose, dose 2=2.5mg/kg/dose, and doses 3-14=3mg/kg/dose)
Study: NCT06105060
Drug: Rosuvastatin 20mg
Normalized name: ROSUVASTATIN 20MG CAP,SPRINKLE
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: to evaluate and compare the protective outcomes of using Rosuvastatin, Vitamin E, and N-acetyl cysteine in Egyptian patients with NASH.
Study: NCT06046729
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT05052996
Drug: ISL
Normalized name: Dartisla
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules administered orally without regard to food
Study: NCT05052996
Drug: B/F/TAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets administered orally without regard to food
Study: NCT05258071
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral use
Study: NCT05721755
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT05745064
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The composition of the placebo is identical to the active formulation except for the exclusion of the active ingredient.
Study: NCT05936151
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT06489028
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05050747
Drug: HCG is introduced at day of trigger intra-uterine
Normalized name: gentamicin
DrugBank: Gentamicin (DB00798)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: hcg is introduced
Study: NCT03775460
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants in the intervention group will receive methotrexate along side prednisolone
Study: NCT03775460
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in the control arm will receive placebo along side prednisolone
Study: NCT03775460
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants in both arm will receive prednisolone, which will be the same dosage: 40 mg (initial dose) decreasing dosage for 20 weeks
Study: NCT05929755
Drug: Gel-Flow NT
Normalized name: Gel-Flow NT
Approvals — FDA: no, EMA: no, PMDA: no
Description: hemostatic agent
Study: NCT04944706
Drug: Qishen Yiqi dripping pills 2 bags/time + Qishen Yiqi dripping pills placebo 2 bags/time
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take 3 times a day after meals,24 weeks
Study: NCT04946734
Drug: Triptans
Approvals — FDA: no, EMA: no, PMDA: no
Description: If migraine recurred, Triptans would be administered during the acute phase.
Study: NCT06395948
Drug: APG777
Approvals — FDA: no, EMA: no, PMDA: no
Description: APG777 subcutaneous injection
Study: NCT06395948
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo subcutaneous injection
Study: NCT06114745
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered through IV infusion
Study: NCT05778188
Drug: RLS-0071
Approvals — FDA: no, EMA: no, PMDA: no
Description: RLS-0071 (unit strength 10 mg/mL) will be administered by infusion for a dose level of 3, 10, or 20 mg/kg. Planned infusion duration is 10 minutes for all dose levels.
Study: NCT05778188
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo control (commercial sterile saline) will be administered by infusion at a volume matched to RLS-0071 (3, 10, or 20 mg/kg). Planned infusion duration is 10 minutes for all matched dose levels.
Study: NCT06227221
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects receive placebo 400mg once daily. Insulin therapy will be continued as a routine therapy.
Study: NCT06019559
Drug: K-757 120 mg BID and K-833 100 mg BID
Normalized name: K
Approvals — FDA: no, EMA: no, PMDA: no
Description: K-757 was titrated to the maintenance dose of 120 mg twice daily (BID) by Day 22. K-833 was initiated at 100 mg once daily in the morning (QAM) and was titrated to the maintenance dose of 100 mg BID on Day 8.~Both administered orally.
Study: NCT06019559
Drug: K-757 120 mg BID and matching placebo to K-833
Normalized name: K
Approvals — FDA: no, EMA: no, PMDA: no
Description: K-757 was titrated to the maintenance dose of 120 mg twice daily (BID) by Day 22.~Both administered orally.
Study: NCT06019559
Drug: Matching placebo to K-757 and matching placebo to K-833
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both administered orally.
Study: NCT04697810
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching capsules q12hours x 36 weeks
Study: NCT05861687
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered twice a day per-oral with the dose of 7.5 mg/kg
Study: NCT06501196
Drug: BH-30236
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BH-30236 will be provided as either a 5 or 30 mg tablet. Patients will take BH-30236 orally depending on their dose level assignment.
Study: NCT06519968
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered as DPI.
Study: NCT04769050
Drug: T-DM1 or Capecitabine combined with Pyrotinib regimen.
Approvals — FDA: no, EMA: no, PMDA: no
Description: T-DM1, 3.6mg/kg(8 mg/kg for initial dose) ivgtt d1 q3w Capecitabine, 1250 mg/m2 bid po d1-14 q3w Pyrotinib, 400mg po daily (continuously)
Study: NCT05609370
Drug: LBL-007
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intravenously.
Study: NCT05609370
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered in accordance with relevant local guidelines and/or prescribing information
Study: NCT06297603
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT05670730
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered via intravenous (IV) infusion.
Study: NCT06565078
Drug: Immune Globulin Subcutaneous (Human), 20% Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: CUVITRU 20% Solution
Study: NCT06097260
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06069102
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: The usual care group will be given anti-hypertensive medications (i.e. beta blocker, calcium channel blocker, etc) if a subject's BP consistently exceeds 150/100 mmHg consistently.
Study: NCT06069102
Drug: Tight blood pressure control
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: The intervention group will be initiated on blood pressure medications (i.e. beta blocker, calcium channel blocker, etc) if a subject's hospital BP consistently exceeds 140/90 mmHg or home BP consistently exceeds 135/85 mmHg.
Study: NCT04873362
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched to atezolizumab will be administered at a dose of 1200 mg Q3W for 14 cycles.
Study: NCT05126277
Drug: placebo s.c.
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo s.c. q4w in addition to SoC
Study: NCT05919537
Drug: HMBD-001
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMBD-001 is a humanized IgG1 anti-HER3 monoclonal antibody (mAb). It is administered IV weekly
Study: NCT05944016
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (standard dose p.o. once daily)
Study: NCT05018481
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A placebo will be given in capsule form to study participants
Study: NCT06020716
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three times daily
Study: NCT03761511
Drug: Nicotinamide
Normalized name: Nicotinamide
DrugBank: Nicotinamide (DB02701)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotinamide 4 g (capsules) or highest tolerated dose with a minimum of 2 g/d per os once daily
Study: NCT04788511
Drug: Placebo (semaglutide)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be injected into a skin fold, in the stomach, thigh or upper arm once a week at the same day of the week (to the extent possible) throughout the trial.~The study will last for approximately 59 weeks.
Study: NCT06468956
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT05714306
Drug: Low dose cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide administered on D1 of each cycle, the day prior to each vaccination (Vx) at a dose of 200 mg/m2 intravenously (i.v.)
Study: NCT06493370
Drug: Intravenous ascorbic acid/vitamin C
Approvals — FDA: no, EMA: no, PMDA: no
Description: A dose escalation regimen will be initiated for each participant at a single dose of 25 g, titrated to up target peak plasma concentration. Once established, IVC will be administered intravenously 2 times per week for the remaining cycles
Study: NCT05029973
Drug: HAIC
Normalized name: Hepatic Arterial Infusion Chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: hepatic arterial infusion (HAI) of oxaliplatin, fluorouracil/leucovorin (FOLFOX) treatment
Study: NCT06215430
Drug: Caffeine Tablet
Normalized name: Caffeine Tablets
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT05684523
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00934258
Drug: rosuvastatin,fenofibrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 10 mg once daily Rosuvastatin 5 mg + SFC fenofibrate 80 mg
Study: NCT06376253
Drug: [68Ga]Ga-EVS459
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radioligand imaging agent
Study: NCT06376253
Drug: [177Lu]Lu-EVS459
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radioligand therapy
Study: NCT05351047
Drug: AZD2373 subcutaneous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized subjects will receive multiple ascending dose of AZD2373 by SC injection (dose 1, dose 2, dose 3, dose 4, dose 5).
Study: NCT05351047
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized subjects will receive a multiple ascending dose of placebo (saline solution) by SC injection.
Study: NCT06006663
Drug: Ibuprofen 400 mg.
Approvals — FDA: no, EMA: no, PMDA: no
Description: synthetic intracanal medicament
Study: NCT06006663
Drug: modified triple antibiotic paste
Approvals — FDA: no, EMA: no, PMDA: no
Description: synthetic intracanal medicament
Study: NCT06415773
Drug: HTD1801
Approvals — FDA: no, EMA: no, PMDA: no
Description: HTD1801 1000 mg BID administered orally BID as four capsules
Study: NCT06305637
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The investigational product was applied on a single occasion topically to the damp skin of the affected area and a wide margin surrounding this area for 5 minutes and then rinsed off with water.
Study: NCT04518280
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine: 1000mg/m2 bid d1-14 q3w
Study: NCT04746105
Drug: TS-142
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects received single-dose of 10 mg of TS-142 (oral tablet)
Study: NCT04746105
Drug: Dose-matched Placebo to TS-142
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects received single-dose matched placebo to TS-142 (oral tablet)
Study: NCT05535933
Drug: HMPL-523(300mg PO QD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMPL-523(300mg PO QD)
Study: NCT05535933
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo(300mg PO QD)
Study: NCT06166381
Drug: Parenteral Antibacterial Agents
Normalized name: Dermoplast Antibacterial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral antibiotic (ceftriaxone) 1 g to be given in 3 doses, at induction of anesthesia, 12 hours postoperative, and 24 hours postoperative.
Study: NCT06182579
Drug: RiMO-401
Normalized name: Rimoxyn
Approvals — FDA: no, EMA: no, PMDA: no
Description: • Single intratumoral injection of RiMO-401 followed by palliative radiotherapy
Study: NCT06328738
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: capsule
Study: NCT06328738
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: intravenous
Study: NCT05915286
Drug: Chlorthalidone
Normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each participant will have a 2 week period of no diuretic use followed by 3 weeks of escalating doses: 1) initially furosemide twice daily, then (2) an increased dose of furosemide twice daily, and in the final week, (3) the addition of chlorthalidone once daily.
Study: NCT05008835
Drug: ACP-044 Dose A
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral dose of ACP-044 Dose A
Study: NCT05008835
Drug: ACP-044 Dose B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose of ACP-044 Dose B
Study: NCT05008835
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo